Get access

A multicenter clinical trial of recombinant human GM-CSF hydrogel for the treatment of deep second-degree burns

Authors


Reprint requests:
Chunmao Han, MD, Department of Burn, the Second Affiliated Hospital, Zhejiang University College of Medicine, #88 Jiefang Road, Hangzhou, China 310009.
Fax: 0571 8778 4585;
Email: hanchunmao1@126.com

ABSTRACT

Wound healing is a complex and dynamic biological process. The efficacy and safety of a recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) hydrogel to promote deep-second-degree burn wound healing is evaluated in this study. In this multicenter, randomized, double-blind, and placebo-controlled clinical trial, 90 patients with deep second-degree burns were randomly assigned into two groups. Complete healing time and percentage of wound healing at different time points were observed and side effects were recorded. A statistically significant difference was noted at each time point (p<0.01). No side effects were observed. These results suggest that rhGM-CSF hydrogel can significantly accelerate deep second-degree burn wound healing and is considered to be safe.

Ancillary